Академический Документы
Профессиональный Документы
Культура Документы
TISSUE RESERVOIRS
Bound
Free
Free
Bound
ABSORPTION
EXCRETION
BIOTRANSFORMATION
Steady state
GFR
Clearance
Definition: A volume of fluid (could be plasma, blood or total body fluid) from which a drug is irreversibly removed in unit time
Atenolol Cltotal = Clrenal Paracetamol Cltotal = Clhepatic + Clrenal Ethanol Cltotal = Clhepatic + Clrenal + Cllung
ADDITIVITY OF CLEARANCES
CL E CL R CL NR
CLR = RENAL CLEARANCE CLNR = NON-RENAL CLEARANCE
NORMAL
CL R VS. CL Cr IS LINEAR*
CLR = CLCr
Ux V CL P
U = URINE CONCENTRATION V = URINE VOLUME P = PLASMA CONCENTRATION
Scr x 72
CrCl women = CrCl men x 0.85 Modification of Diet in Renal Disease Equation (MDRD)
from the body determines whether it will disappear from, or accumulate in the patients blood
Renal Insufficiency
Stage 1
> 90
Renal Failure
Stage 4
30-15
Stage 2
90-60
Stage 3
60-30
Stage 5
15; ESRD
Principles
Establish
Most patients with kidney failure will already be taking a number of drugs Interactions are common Care needed to avoid drug toxicity
Patients
failure
Antihypertensives Phosphate binders
SS
DOSE CL
E
REDUCE DOSE IN PROPORTION TO CLE MAINTAIN USUAL DOSE BUT INCREASE DOSING INTERVAL IN PROPORTION TO CLE ADJUST BOTH DOSE AND DOSING INTERVAL
Agent
AMPICILLIN
Usual Dosage
Mild to moderate infection: 500mg to 2g ivpb q6h. Severe infection: 2g ivpb q4h (150-200mg/kg/day)
Renal Dosing
>50/ q6h || 10-50/ q6-12h || <10/ q12-24 hours || Hemodialysis: Dose after dialysis || PD: 250mg q12h. >50/ no changes || 10-50/ q6-12h || <10/ q12h
AMPICILLIN (Oral)
CEFEPIME (MAXIPIME)
>60/ 0.5-2g q12h || 3060/ 0.5g-2g q24h || 1129/ 0.5g-1g q24h || <10/ 250-500mg q24h or 0.5-2g q48h. || HD: 1g AD || PD: 1-2 grams q48h
CEFOTETAN (IV)
Usual dose: 1g ivpb q12h. Severe: 2-3g ivpb q12h. (Max 6g/day) Mild infection: 1g ivpb q6-8h Moderatesevere: 1g ivpb q4h or 2g ivpb q6-8h. Lifethreatening: 2g ivpb q4h or 3g ivpb q6h.
>30/ Usual dose || 1030/ 50% of dose q12h || <10/ 25% of dose q12h.|| Hemodialysis or PD: 50% of usual dose q24h
10-50/ q8-12h || <10/ q24-48h || HD: give 1g after Dialysis: e.g. Give Cefoxitin 1g ivpb M-W-F after dialysis + a supplemental dose on Sunday.
CEFOTAXIME (IV)
Mild infection: 1-2g ivpb q12h. Moderate: 1-2g ivpb q8h; Severe: 2g ivpb q68h; Life threatening: 2g ivpb q4h (Max dose/day= 12g)
>50/ Usual dose || 10-50/ q8-12h || <10/ q24h || HD: 0.5 to 2g ivpb q24h AD. || PD: 1g ivpb q24h.
CEFUROXIME (IV)
>20/q8h || 10-20/ q12h || <10/ 750mg q24h. || Usual: 750mg to 1.5g Hemodialysis: Give single ivpb q8h. Severe: 1.5g dose after dialysis or give ivpb q6-8h. 750mg q12h. || PD: 750mg-1.5g q24h No changes req'd (usual oral doses are not significant).
CEFTIN (ORAL)
Back
CEFTRIAXONE (IV)
q8-12h. Severe: 2g Crcl 30-50/ q12h || 1030/ q24h || <10/ q48h ivpb q8-12h. (Max dose/day= 6 grams). Usual dose: 250500mg po q6h; 500mg-1g q12h. Keflex: 10-50/ q6-12h || <10/ q12-24h . Velosef: >20/ no change || 5-20/ 250mg q6h || < 5/ 250mg q12h
Oral dosing: 250750mg po q12h; cystic fibrosis: 750mg po q8h. IV dosing: 200-400mg ivpb q12h. Febrile neutrapenic pt: 400mg ivpb q8h
>50/ no change || 10-50/ 50-75% of usual dose q12h || <10/50% of usual dose q12. Alternatives: [200mg ivpb or 250mg po q12h] or [400 mg ivpb or 500mg po q24h]. || HD/PD: 250500mg po or 200-400mg ivpb q24h AD or 200mg ivpb or 250mg po q12h.
IMIPENEM (PRIMAXIN)
Mild to moderate infection: 250-500mg ivpb q6-8h. Severe infection: 500mg to 1g ivpb q6-8h. Max dose/day= 50mg/kg/day or 4g/day Usual dose: 500mg po or ivpb q24h. UTI or pyelonephritis: 250mg po/ivpb q24h. IV: 1 gram or 15 mg/kg load IV, then 500mg or 7.5 mg/kg q6h (range: q6-12h -long T ). Oral: 250750mg po tid. (occasionally bid). Max 4g/day.
31-70/ 500mg q6-8h || 21-30/ 500mg q8-12h max || 0-20/ 250-500mg q12h max. || HD: 250 mg AD + q12h. || PD: max dose= 1gram/day i.e. 500mg ivpb q12h. >50/ no change || 2049/ 500mg x 1 then 250mg q24h || <19/HD/PD: 500mg x 1 then 250mg q48h
LEVOFLOXACIN (LEVAQUIN)
12 24 24 6 - 12 6 12 12
8 - 24 8 - 24 24 8
Carbamazepine
Chloroquine Cisplatine Cimetidine
20 - 36
2-4 2 -72 2
?
5 h 50 days 1 - 240 5
8 - 12
12 24 8
Unch
Unch Unch Unch
Unch
Unch 75 75
75
50 50 50
DOSAGE ADJUSTMENT 1/2 normal dose if CLCr < 30 mL/min PHARMACOKINETICS Following I.V. of I.M. administration in normal subjects, ~ 75% of drug is recovered from the urine as parent compound. * Physicians Desk Reference. 58th edition, 2004.
METABOLISM
PROCAINAMIDE ACETYLATION
Fast
12.2 118 0 118
Slow
17.0 94 0 94
Vd(ss) (L/kg)
1.95
1.93
1.41
1.93
H O H N N O O H N
H N O
OH
PHENYTOIN
p - HPPH
PHENYTOIN
NORMALS (N = 4)
UREMIC PATIENTS (N = 4)
% UNBOUND (fu)
CLH CLint
12%
2.46 L/hr 20.3 L/hr
26%
7.63 L/hr 29.9 L/hr NS
DECREASED BIOAVAILABILITY:
D-XYLOSE FUROSEMIDE
INCREASED BIOAVAILABILITY:
PROPRANOLOL DEXTROPROPOXYPHENE
Antibiotics A.Aminoglycosides B.Amphotericin B C.Tetracycline D.Acyclovir E.Pentamidine Chemotherapy and Immunosuppressants A.Cisplatin B.Methotrexate C.Mitomycin D.Cyclosporine Heavy Metals A.Mercury B.Lead C.Arsenic D.Bismuth Miscellaneous Drugs A.Radiographic contrast B.ACE Inhibitors C.NSAIDs D.Aspirin